Bristol-Myers Squibb Company / Cardioxyl Pharmaceuticals, Inc.
2015 · Acquisition/Merger · $2.1B · Complete
Announcement Sentiment
63
Positive
BMS acquired Cardioxyl Pharmaceuticals for up to $2.075B ($300M upfront plus up to $1.775B in development, regulatory, and sales milestones), adding Phase 2 nitroxyl donor CXL-1427 for acute decompensated heart failure. Program later discontinued.